Related Experiment Video

Updated: May 14, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Vaccination against meningococcus C. vaccinal coverage in the French target population

J-P Stahl1, R Cohen, F Denis

  • 1Service de maladies infectieuses et tropicales, université 1 de Grenoble, CHU de Grenoble, BP 217, 38043 Grenoble, France. JPStahl@chu-grenoble.fr

Medecine Et Maladies Infectieuses
|February 23, 2013
PubMed

Insights

Meningococcus C vaccine coverage in France was low in 2011, with only 32.3% of infants and 21.3% of teenagers vaccinated. This indicates a need to improve public health strategies for immunization programs.

Area of Science:

  • Public Health
  • Epidemiology
  • Vaccinology

Background:

  • Meningococcus C immunization was recommended in France in 2009 for infants and adolescents.
  • Vaccine reimbursement began in January 2010, aiming to increase uptake.
  • Assessing vaccine coverage was crucial to evaluate the policy's effectiveness.

Purpose of the Study:

  • To evaluate the vaccine coverage for Meningococcus C in France in 2011.
  • To determine the uptake of the Meningococcus C vaccine among infants and adolescents.
  • To assess the impact of the reimbursement policy on vaccination rates.

Main Methods:

  • A study included 3000 mothers of children aged 0-35 months and 2250 mothers of teenagers aged 14-16 years.
  • Participants were recruited via internet panels, with quotas based on French National Institute of Statistics (INSEE) data.
  • Mothers completed a questionnaire reporting their child's vaccinations from health records.

Main Results:

  • Vaccination was considered essential or useful by over 90% of mothers for both age groups.
  • Vaccine coverage was 32.3% for infants aged 12-23 months and 57.3% for those aged 24-35 months.
  • Coverage was significantly lower for teenagers, with only 21.3% vaccinated.

Conclusions:

  • Two years post-reimbursement, Meningococcus C vaccine coverage levels were substantially lower than anticipated for policy effectiveness.
  • Low uptake in infants and particularly in teenagers suggests challenges in the immunization strategy.
  • Further interventions are needed to improve Meningococcus C vaccination rates and achieve public health goals.
Abstract

More Related Videos

A Multiplex Serological Assay for the Detection of Antibody Responses to Arboviruses05:22

A Multiplex Serological Assay for the Detection of Antibody Responses to Arboviruses

Published on: November 4, 2025

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.